Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 55 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

27%

15 trials in Phase 3/4

Results Transparency

0%

0 of 10 completed trials have results

Key Signals

16 recruiting

Enrollment Performance

Analytics

Phase 2
11(28.9%)
Phase 3
8(21.1%)
N/A
8(21.1%)
Phase 4
7(18.4%)
Phase 1
4(10.5%)
38Total
Phase 2(11)
Phase 3(8)
N/A(8)
Phase 4(7)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (55)

Showing 20 of 55 trials
NCT07539753Phase 2Not Yet Recruiting

Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases

Role: collaborator

NCT06140992Recruiting

PaCIFiC-CUP Classifies Cancer of Unknown Primary

Role: collaborator

NCT07537257Phase 2Enrolling By Invitation

VEN+IDAC vs IDAC in AML

Role: collaborator

NCT07517510Phase 2Enrolling By Invitation

HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL).

Role: collaborator

NCT06308952Phase 4Recruiting

Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation

Role: collaborator

NCT07353749Phase 4Not Yet Recruiting

Efficacy and Safety of Methylprednisolone After Flow-Diverter Stent Implantation in Unruptured Intracranial Aneurysms

Role: collaborator

NCT07201337Phase 3Recruiting

Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.

Role: collaborator

NCT05305859Phase 2Recruiting

Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML

Role: collaborator

NCT07096219Enrolling By Invitation

Catheter Ablation for Functional Mitral Regurgitation in Persistent Atrial Fibrillation: Development and Validation of a Predictive Model-A Multicenter Prospective Cohort Study

Role: collaborator

NCT06577792Not ApplicableRecruiting

Lobectomy-First vs. Lymphadenectomy-First for Operable NSCLC (LOFTY)

Role: collaborator

NCT06898216Not ApplicableRecruiting

Steerable vs Conventional FANS for <2cm Lower Pole Stone Treatment: SCULPT Trial

Role: collaborator

NCT05811676Phase 3Completed

Tranexamic Acid for the Prevention of Postpartum Hemorrhage in Pregnant Women With Placenta Previa

Role: collaborator

NCT06158386Phase 2Recruiting

Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma

Role: collaborator

NCT06151106Phase 2Recruiting

Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma

Role: collaborator

NCT06810791Phase 3Recruiting

HVA vs IA/DA or VA in the Treatment of ND HR-AML

Role: collaborator

NCT05780372Phase 3Recruiting

Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma

Role: collaborator

NCT06763666Phase 4Not Yet Recruiting

CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML

Role: collaborator

NCT04212494Not ApplicableRecruiting

Thrombus Aspiration in STEMI Patients With High Thrombus Burden

Role: collaborator

NCT06647940Phase 2Recruiting

Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）

Role: collaborator

NCT05290545Phase 3Completed

Haplo-PBSC+Cord vs Haplo-PBSC+BM for Hematological Malignancies Undergoing Allo-HSCT

Role: collaborator